<DOC>
	<DOCNO>NCT02042807</DOCNO>
	<brief_summary>To evaluate effect MCS® compare placebo reduce risk biopsy-detectable prostate cancer high-risk subject 104 week ( 24 month ) treatment .</brief_summary>
	<brief_title>To Evaluate Effect MCS® Prostate Cancer Prevention</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1. highrisk subject prostate cancer . 2 . Male subject age 50 75 year old . 3 . Subject able understand willing comply study procedure sign informed consent form ( ICF ) . 1 . Subjects take longterm hormonal agent may affect normal physiology sex hormone function . 2 . Subjects PSA &gt; 10.0 ng/ml . 3 . Subjects history prostate cancer . 4 . Subject participate another investigational agent study past 30 day plan study period . 5 . Subjects consider ineligible study judge investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>